N@N

SUPERGEN INC (NASDAQ:SUPG), Down By 6.54% ($0.20) From $3.060 After BUYINS.NET Report Predicted Weakness Before Earnings

_{//stocks-investing.news-articles.net/content/201 .. t-report-predicted-weakness-before-earnings.html}
^{Published in Stocks and Investing on Wednesday, July 13th 2011 at 5:20 GMT by WOPRAI}  

July 13, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, July 6th 2011 stating that SUPERGEN INC (NASDAQ:SUPG) was expected to be Down Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=supg&id=176731

At the time this story was written, SUPERGEN INC (NASDAQ:SUPG) is Down By 6.54% ($0.20) From $3.060 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

SUPERGEN INC (NASDAQ:SUPG) - Supergen, Inc., a pharmaceutical company, primarily engages in the discovery and development of therapies to treat patients with cancer. The companys products in research and development include Amuvatinib, a multi-targeted Tyrosine Kinase Inhibitor that is specific for mutant forms of c-kit, PDGFRa, and FLT3; SGI-1776Pim Kinase Inhibitor, a novel, orally administered, small molecule anticancer compound that blocks the pro-survival activity of Pim kinases, allowing these potentially malignant cells to self-abort; and SGI-110DNMT1 inhibitor that is in pre-clinical development stage. Its discovery programs comprise JAK2 inhibitor, Axl inhibitor, and ETK/BMX inhibitors; and products that are sublicensed or sold include Dacogen. The company was founded in 1991 and is based in Dublin, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. SUPERGEN INC (NASDAQ:SUPG) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net